Emerging strategies are now exploring menin inhibitors (e.g., revumenib, ziftomenib) in NPM1-mutated and KMT2A-rearranged AML, showing promising activity by disrupting oncogenic transcriptional programs [61]. Here, NPM1 is linked to acute myeloid leukemia.